Valeant: Why Moneyball Failed in the Pharmaceutical Industry – The New Yorker


The New Yorker
Valeant: Why Moneyball Failed in the Pharmaceutical Industry
The New Yorker
The past few months have been terrible ones for investors in Valeant Pharmaceuticals. In February, the company disclosed that it had accounted incorrectly for fifty-eight million dollars worth of sales by Philidor, a specialty pharmacy that it owned

and moreĀ >>

Source: pharmaceutical – Google News

Sharing information is key – Pharmaceutical Business News UK. Social Commerce and Social Media Management playing a big part. Suaju Ltd